Connected by T1D

Revealing the familial thread of
type 1 diabetes (T1D) by screening
first- and second-degree relatives can help those who are most at risk avoid complications like DKA at clinical onset.1

Father and daughter connected by T1D

Magnifying Glass Icon

300K people are at increased risk of clinical T1D2

Familial history is a strong predictor for T1D; focusing on the family of patients with T1D can help identify presymptomatic patients.3,4

Know Who to Identify

Autoantibody icon

Unravel the presymptomatic story behind T1D

Patients' beta cells may be targeted for destruction before a clinical diagnosis of T1D. Recognition of this process and its implications can prepare families for the risks ahead of clinical onset.5,6

Know What's Happening

Microscope screening icon

Screening can reduce DKA at onset by 50%7,8

Early autoantibody screening can identify those most at risk of developing T1D. Increased awareness and early intervention may improve outcomes at presentation and avoid significant consequences such as diabetic ketoacidosis.1

Know the Benefits

Screening can identify T1D patients before clinical onset1

There are various organizations and resources for T1D screening and clinical trials to advance T1D care.

1. Raab J, Haupt F, Scholz M, et al; Fr1da Study Group. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6(5):1-12.

2. Ward K, Pan C, Shinde M, Rievathavorn J, Hedge S, Gaebler JA; JDRF. Modeling the total economic value of novel type 1 diabetes (T1D) therapeutic concepts. Published January 2020. Accessed April 22, 2020.

3. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.

4. Couper JJ, Haller MJ, Greenbaum CJ, et al. ISPAD Clinical Practice Consensus Guidelines 2018: stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2018;19(suppl 27):20-27.

5. Herold KC, Bundy BN, Long SA, et al; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603-613.

6. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479.

7. Barker JM, Goehrig SH, Barriga K, et al; DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404.

8. Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2353.